# Can LL-37 promote autophagy and cellular cleanup in aging cells?

Canonical source: https://retacompare.com/research/can-ll-37-promote-autophagy-and-cellular-cleanup-in-aging-cells

Peptide Longevity Q&A · 2026-04-17


    Research indicates that LL-37, a cathelicidin antimicrobial peptide, has the potential to enhance autophagy and promote cellular cleanup processes, which may contribute to improved immune responses against Mycobacterium tuberculosis.

 What the research shows

The study investigates the potential of antimicrobial peptides (AMPs), specifically LL-37, in treating tuberculosis, particularly against drug-resistant strains. It highlights the immunomodulatory effects of AMPs, including their ability to enhance phagosome-lysosome fusion and induce autophagy. The research emphasizes the direct antimycobacterial effects of LL-37 and other AMPs, showcasing their strong activity in both in vitro and in vivo models. The review also discusses the challenges of peptide stability and delivery, while suggesting advancements in peptide engineering and nanoparticle-based delivery methods as potential solutions.

 Why it matters for longevity

The findings regarding LL-37's role in promoting autophagy and enhancing immune responses are significant in the context of longevity. Autophagy is a crucial cellular process that helps maintain cellular health by removing damaged organelles and proteins, thereby reducing the risk of age-related diseases. By supporting autophagy, LL-37 may contribute to improved cellular function and longevity, particularly in the context of combating infections and maintaining overall health as individuals age.

 Key findings at a glance

LL-37 demonstrates strong antimycobacterial activity against Mycobacterium tuberculosis.

It enhances phagosome-lysosome fusion, a critical process for immune response.

LL-37 induces autophagy, which aids in cellular cleanup.

Challenges remain regarding peptide stability and effective delivery methods.

Advancements in peptide engineering may enhance the clinical application of LL-37.

 How LL-37 works (background)

LL-37 is a cathelicidin antimicrobial peptide that plays a vital role in the innate immune response. It functions by disrupting bacterial membranes and obstructing intracellular processes, leading to bacterial death. Additionally, LL-37 modulates host immune responses, enhancing the fusion of phagosomes and lysosomes, which is essential for degrading pathogens. Its ability to induce autophagy further supports cellular cleanup, promoting the removal of damaged components and potentially improving cellular longevity.

 Safety, caveats, and what we don't yet know

While the research highlights the potential of LL-37 in promoting autophagy and enhancing immune responses, there are limitations to consider. The study primarily focuses on in vitro and in vivo models, and further research is needed to evaluate the safety and efficacy of LL-37 in human populations. Additionally, the challenges related to peptide stability and delivery methods must be addressed to maximize the clinical applicability of LL-37 as a therapeutic agent.

 Bottom line

LL-37 has shown promise in promoting autophagy and enhancing immune responses, which may contribute to cellular cleanup and longevity. Ongoing research is essential to fully understand its potential in clinical applications.

 Related questions

 Does LL-37 enhance immune responses in older adults?

Research suggests that LL-37 may enhance immune responses by promoting phagosome-lysosome fusion and autophagy, which could be beneficial for older adults facing increased susceptibility to infections.

 Can LL-37 be combined with other longevity interventions?

While LL-37 shows potential as a standalone treatment, its combination with other longevity interventions remains an area for future research, particularly in understanding synergistic effects.

 What are the challenges of using LL-37 in therapy?

Key challenges include peptide stability, effective delivery methods, and the need for further research to evaluate its safety and efficacy in human populations.

 Source: PubMed · Curr Protein Pept Sci · published 2026-04-17.

## Sources

- PubMed · Curr Protein Pept Sci: https://pubmed.ncbi.nlm.nih.gov/42003198/